iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39408645/
Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 25;25(19):10314.
doi: 10.3390/ijms251910314.

Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Jun-Dae Kim  1 , Abhishek Jain  2 , Longhou Fang  1   3
Affiliations
Review

Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Jun-Dae Kim et al. Int J Mol Sci. .

Abstract

Atherosclerosis, characterized by the accumulation of lipoproteins and lipids within the vascular wall, underlies a heart attack, stroke, and peripheral artery disease. Endothelial inflammation is the primary component driving atherosclerosis, promoting leukocyte adhesion molecule expression (e.g., E-selectin), inducing chemokine secretion, reducing the production of nitric oxide (NO), and enhancing the thrombogenic potential. While current therapies, such as statins, colchicine, anti-IL1β, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, target systemic inflammation, none of them addresses endothelial cell (EC) inflammation, a critical contributor to disease progression. Targeting endothelial inflammation is clinically significant because it can mitigate the root cause of atherosclerosis, potentially preventing disease progression, while reducing the side effects associated with broader anti-inflammatory treatments. Recent studies highlight the potential of the APOA1 binding protein (AIBP) to reduce systemic inflammation in mice. Furthermore, its mechanism of action also guides the design of a potential targeted therapy against a particular inflammatory signaling pathway. This review discusses the unique advantages of repressing vascular inflammation or enhancing vascular quiescence and the associated benefits of reducing thrombosis. This approach offers a promising avenue for more effective and targeted interventions to improve patient outcomes.

Keywords: AIBP; ASCVD; inflamed EC-specific targeting; vascular inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A). Lipoprotein penetration and retention in the sub-endothelium. Hyperlipidemia contributes to greater LDL and HDL presence in the subendothelial space, where they are rendered proinflammatory. These modified lipoproteins will be taken up by macrophages, which subsequently become lipid-laden foam cells. (B). AIBP impedes TLR4-mediated inflammatory signaling in myeloid cells. TLR4 dimerization is essential for the innate inflammatory response. AIBP binds TLR4, enabling a targeted cholesterol efflux, which disrupts TLR4 dimerization and represses signaling. This AIBP-mediated effects result in inhibited inflammatory responses. (C). AIBP regulation of lipid rafts via cytoskeleton rearrangement. AIBP binds PI(3)P, activating CDC42, and triggering actin polymerization, which consequently reduces the lipid raft levels. (D). AIBP regulates mitophagy. Mitochondrial AIBP binds PARKIN and MFN and increases the ubiquitination of MFN. Ubiquitinated MFN will recruit P62, which in turn facilitates the LC3 interactions, thereby targeting these mitochondria for degradation via autophagy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell. 2001;104:503–516. doi: 10.1016/S0092-8674(01)00238-0. - DOI - PubMed
    1. Iiyama K., Hajra L., Iiyama M., Li H., DiChiara M., Medoff B.D., Cybulsky M.I. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ. Res. 1999;85:199–207. doi: 10.1161/01.RES.85.2.199. - DOI - PubMed
    1. Vendrov A.E., Hakim Z.S., Madamanchi N.R., Rojas M., Madamanchi C., Runge M.S. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler. Thromb. Vasc. Biol. 2007;27:2714–2721. doi: 10.1161/ATVBAHA.107.152629. - DOI - PubMed
    1. Zhou Z., Subramanian P., Sevilmis G., Globke B., Soehnlein O., Karshovska E., Megens R., Heyll K., Chun J., Saulnier-Blache J.S., et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011;13:592–600. doi: 10.1016/j.cmet.2011.02.016. - DOI - PubMed
    1. Huang L., Chambliss K.L., Gao X., Yuhanna I.S., Behling-Kelly E., Bergaya S., Ahmed M., Michaely P., Luby-Phelps K., Darehshouri A., et al. SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature. 2019;569:565–569. doi: 10.1038/s41586-019-1140-4. - DOI - PMC - PubMed

LinkOut - more resources